Alembic Pharmaceuticals Limited

NSE: APLLTD · Unclassified

₹965.15+8.02%06 Nov 2026

Ask the data

Instant answers about Alembic Pharmaceuticals Limited — computed from its filings, no language model

Market cap₹18,970 cr

Current price₹965.15

High / Low₹965 / ₹647

P/E22.5

P/B3.19

Book value₹302.4

ROE14.2%

ROCE14.2%

Debt / equity0.25

Dividend yield1.14%

EPS (TTM)₹42.88

Face value₹2

Price & valuation

split & bonus adjusted · pick a metric and range

Annual performance

annual · ₹ crore · line = operating margin

showing latest 6 of 9 periods

	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25	FY26
Revenue	3,131	3,935	4,606	5,393	5,306	5,653	6,229	6,672	7,345
EBITDA	643	874	1,223	1,558	874	708	933	1,008	1,118
Operating margin	20.5%	22.2%	26.6%	28.9%	16.5%	12.5%	15.0%	15.1%	15.2%
Interest	3	18	27	16	18	50	56	79	94
Depreciation	105	115	157	183	287	275	273	279	319
Profit before tax	541	749	1,000	1,368	620	386	633	706	694
Tax	120	157	199	253	104	13	16	125	23
Net profit	413	-1	829	1,178	546	342	616	583	671
EPS ₹	21.89	31.00	43.97	60.81	27.76	17.40	31.33	29.68	34.33
Operating cash flow	—	—	—	—	552	724	803	88	783
Capex	—	—	—	—	426	443	327	564	435
Dividend paid	—	—	—	—	275	197	157	216	216
Total assets	—	—	—	—	—	6,183	6,446	7,773	8,763
Equity	—	—	—	—	—	4,370	4,818	5,191	5,675

Quarterly performance

last 33 quarters · ₹ crore

showing latest 8 of 33 periods

	MAR '18	SEP '18	DEC '18	MAR '19	JUN '19	SEP '19	DEC '19	MAR '20	JUN '20	SEP '20	DEC '20	MAR '21	JUN '21	SEP '21	MAR '22	JUN '22	SEP '22	DEC '22	MAR '23	JUN '23	SEP '23	DEC '23	MAR '24	JUN '24	SEP '24	DEC '24	MAR '25	JUN '25	SEP '25	DEC '25	MAR '26	JUN '26	SEP '26
Revenue	853	1,127	1,018	927	949	1,241	1,209	1,207	1,341	1,457	1,314	1,280	1,326	1,292	1,416	1,262	1,475	1,509	1,406	1,486	1,595	1,631	1,517	1,562	1,648	1,693	1,770	1,711	1,910	1,876	1,848	2,150	2,603
Operating profit	173	302	242	178	225	346	325	328	407	443	365	342	236	257	160	15	233	249	212	199	208	266	260	237	239	260	272	281	316	294	228	332	563
Operating margin	20.3%	26.8%	23.8%	19.2%	23.7%	27.8%	26.9%	27.1%	30.4%	30.4%	27.8%	26.7%	17.8%	19.9%	11.3%	1.2%	15.8%	16.5%	15.1%	13.4%	13.1%	16.3%	17.1%	15.2%	14.5%	15.4%	15.4%	16.4%	16.5%	15.6%	12.3%	15.4%	21.6%
Other income	1	2	4	3	3	0	0	1	0	3	3	4	2	2	10	1	0	0	1	12	10	3	4	2	17	10	14	6	7	16	26	15	15
Interest	1	6	6	5	5	7	7	8	7	4	2	3	2	5	7	9	12	15	14	14	16	15	11	13	19	22	25	24	24	23	23	28	38
Depreciation	32	29	29	30	35	36	42	44	42	44	47	51	53	55	123	67	68	67	74	66	68	69	69	69	71	70	69	74	76	80	89	98	101
Profit before tax	141	270	211	146	155	303	276	266	360	398	318	292	183	200	41	-60	153	168	125	130	135	185	183	157	180	177	193	191	222	163	118	221	439
Tax	39	70	40	15	36	52	49	62	67	73	59	54	34	40	-2	-1	18	33	-36	9	-2	4	5	22	27	40	35	36	40	30	-83	50	104
Net profit	94	200	170	-0	115	4	234	225	301	333	293	251	165	169	35	-66	133	125	153	121	137	180	178	135	153	138	157	154	185	133	202	173	335
EPS ₹	4.98	10.61	9.01	6.58	6.56	13.06	12.42	11.92	15.99	17.24	14.88	12.75	8.37	8.61	1.80	-3.35	6.78	6.20	7.76	6.14	6.95	9.18	9.07	6.85	7.79	7.01	7.98	7.85	9.40	6.76	10.31	8.80	17.05
Revenue YoY	—	—	—	8.6%	—	10.1%	18.8%	30.2%	41.4%	17.4%	8.7%	6.1%	-1.1%	-11.3%	10.6%	-4.8%	14.1%	—	-0.7%	17.7%	8.1%	8.1%	7.9%	5.1%	3.3%	3.8%	16.7%	9.5%	15.9%	10.8%	4.4%	25.7%	36.3%
Profit YoY	—	—	—	-100.3%	—	-97.9%	37.9%	—	161.6%	7875.4%	24.9%	11.6%	-45.4%	-49.2%	-85.9%	-140.0%	-21.2%	—	330.3%	—	2.4%	44.4%	16.8%	11.7%	12.3%	-23.3%	-12.0%	14.6%	20.4%	-3.9%	28.5%	12.1%	81.5%

Earlier results (standalone, Sep '11 – Dec '17)

₹ crore · from BSE, before the NSE XBRL filings begin

Alembic Pharmaceuticals Limited reports consolidated figures above. Quarterly consolidated results only became mandatory in India in 2019, so the earlier history available is the standalone company only (excluding subsidiaries). It is shown separately so the two bases are never mixed.

Full years

	FY13†	FY14†	FY15†	FY16†	FY17†
Revenue	1,493	1,844	2,019	2,983	2,977
Operating profit	244	359	410	982	633
Operating margin	16.3%	19.5%	20.3%	32.9%	21.3%
Other income	4	3	1	6	2
Interest	15	10	2	2	3
Depreciation	35	40	44	72	83
Profit before tax	198	312	363	913	550
Tax	41	74	76	215	119
Net profit	157	238	287	698	431

Quarters

showing latest 8 of 26 periods

	SEP '11†	DEC '11†	MAR '12†	JUN '12†	SEP '12†	DEC '12†	MAR '13†	JUN '13†	SEP '13†	DEC '13†	MAR '14†	JUN '14†	SEP '14†	DEC '14†	MAR '15†	JUN '15†	SEP '15†	DEC '15†	MAR '16†	JUN '16†	SEP '16†	DEC '16†	MAR '17†	JUN '17†	SEP '17†	DEC '17†
Revenue	385	350	319	339	407	369	378	427	485	477	455	482	541	502	494	575	923	898	588	689	837	805	647	590	762	755
Operating profit	60	60	40	48	64	70	62	74	95	103	87	93	115	106	96	108	340	394	140	172	167	196	99	87	177	160
Operating margin	15.7%	17.2%	12.4%	14.2%	15.6%	19.0%	16.3%	17.4%	19.6%	21.6%	19.0%	19.4%	21.2%	21.0%	19.5%	18.8%	36.8%	43.9%	23.7%	25.0%	19.9%	24.3%	15.2%	14.7%	23.2%	21.3%
Other income	0	0	0	0	0	3	0	0	0	0	3	0	0	0	0	0	0	3	3	0	0	0	1	0	8	0
Interest	7	7	5	6	3	4	2	1	3	3	2	1	1	0	0	0	1	1	1	1	0	0	1	1	0	1
Depreciation	8	8	9	9	9	9	9	10	10	10	11	11	11	12	11	13	13	22	24	19	20	22	22	22	26	26
Profit before tax	45	45	25	34	52	61	51	63	83	90	76	82	102	93	86	95	326	375	117	153	147	174	76	64	159	134
Tax	7	8	6	7	10	12	12	14	19	22	19	20	18	19	18	19	74	95	28	33	33	36	17	14	36	29
Net profit	38	37	19	27	41	49	40	49	64	68	57	61	84	74	67	76	253	280	89	120	114	138	59	51	122	105
EPS ₹	2.02	1.96	1.00	1.45	2.20	2.60	2.11	2.62	3.39	3.60	3.03	3.26	4.46	3.92	3.56	4.05	13.40	14.86	4.72	6.35	6.04	7.31	3.14	2.69	6.48	5.57
Revenue YoY	—	—	—	—	5.6%	5.5%	18.6%	25.8%	19.3%	29.1%	20.5%	12.9%	11.6%	5.3%	8.5%	19.3%	70.4%	78.8%	19.1%	19.8%	-9.3%	-10.3%	10.0%	-14.3%	-8.9%	-6.2%
Profit YoY	—	—	—	—	9.1%	32.4%	110.2%	81.3%	53.9%	38.4%	43.9%	24.3%	31.7%	9.1%	17.4%	24.1%	200.6%	278.6%	32.7%	56.9%	-54.9%	-50.8%	-33.5%	-57.7%	7.3%	-23.8%

Returns & margins

trailing-twelve-month, per quarter

showing latest 8 of 26 periods

	JUN '19	SEP '19	DEC '19	MAR '20	JUN '20	SEP '20	DEC '20	MAR '21	JUN '21	SEP '21	DEC '22	MAR '23	JUN '23	SEP '23	DEC '23	MAR '24	JUN '24	SEP '24	DEC '24	MAR '25	JUN '25	SEP '25	DEC '25	MAR '26	JUN '26	SEP '26
ROE	—	—	—	—	—	—	—	—	—	—	4.5%	7.9%	12.2%	12.0%	13.2%	12.8%	13.1%	13.2%	12.4%	11.2%	11.6%	11.9%	11.8%	11.9%	12.2%	14.2%
ROCE	—	—	—	—	—	—	—	—	—	—	5.9%	8.7%	12.6%	11.7%	12.1%	13.1%	13.6%	13.0%	13.0%	12.3%	13.0%	13.0%	12.8%	11.2%	11.7%	14.2%
Net margin	12.1%	7.0%	8.2%	12.6%	15.3%	21.0%	21.7%	21.8%	19.4%	16.8%	4.0%	6.1%	9.0%	8.9%	9.6%	9.9%	10.0%	10.2%	9.4%	8.7%	8.8%	9.0%	8.7%	9.2%	8.9%	9.9%
EBITDA margin	23.6%	24.0%	24.8%	26.6%	28.1%	28.8%	29.0%	28.9%	25.8%	23.0%	11.6%	12.5%	15.2%	14.5%	14.5%	15.0%	15.4%	15.8%	15.5%	15.1%	15.4%	15.9%	16.0%	15.2%	15.0%	16.7%
Debt / equity	—	—	—	—	—	—	—	—	—	—	0.14	0.15	0.15	0.18	0.18	0.09	0.09	0.20	0.20	0.23	0.23	0.27	0.27	0.24	0.24	0.25
Interest coverage	36.86	36.31	36.96	37.81	42.74	50.50	64.27	86.40	104.85	86.82	8.09	8.68	11.32	10.44	10.63	12.26	13.00	13.12	11.69	9.97	9.31	9.28	9.04	8.41	8.42	9.43
Asset turnover	—	—	—	—	—	—	—	—	—	—	0.80	0.91	0.95	0.93	0.95	0.97	0.98	0.88	0.89	0.86	0.88	0.84	0.87	0.84	0.89	0.89

Balance sheet

equity vs borrowings over time · ₹ crore

showing latest 6 of 9 periods

	SEP '22	MAR '23	SEP '23	MAR '24	SEP '24	MAR '25	SEP '25	MAR '26	SEP '26
Share capital	39	39	39	39	39	39	39	39	39
Other equity / reserves	5,081	4,331	4,431	4,779	4,849	5,152	5,280	5,636	5,905
Total equity	5,120	4,370	4,470	4,818	4,888	5,191	5,319	5,675	5,944
Borrowings	693	636	784	430	995	1,196	1,414	1,361	1,490
Current liabilities	1,818	1,637	1,810	1,455	2,172	2,412	2,730	2,594	3,099
Non-current liabilities	161	175	175	172	171	171	351	500	496
Total assets	7,099	6,183	6,455	6,446	7,230	7,773	8,397	8,763	9,531
Property, plant & equipment	1,721	2,398	2,603	2,547	2,463	2,524	2,612	2,844	2,914
Capital work-in-progress	2,357	601	478	524	662	837	903	634	543
Investments	118	96	98	93	102	127	129	141	153
Inventories	1,588	1,475	1,539	1,644	2,013	2,288	2,541	2,511	2,654
Receivables	844	1,046	1,075	1,025	1,268	1,400	1,314	1,466	1,896
Cash & equivalents	65	75	141	120	122	83	134	196	254

Cash flow

annual · ₹ crore · line = free cash flow

	FY22	FY23	FY24	FY25	FY26
Cash from operations	552	724	803	88	783
Cash from investing	-372	-448	-321	-568	-506
Cash from financing	-217	-262	-438	444	-164
Capex	426	443	327	564	435
Free cash flow	127	281	476	-476	348
Dividends paid	275	197	157	216	216

Where the assets sit

Sep '26 · ₹ crore

Fixed assets (PPE)

₹2,914 cr31%

CWIP

₹543 cr6%

Investments

₹153 cr2%

Inventories

₹2,654 cr28%

Receivables

₹1,896 cr20%

Cash & equivalents

₹254 cr3%

Other assets

₹1,117 cr12%

Peer comparison

largest in Unclassified · this company in bold

Company	Market cap ₹cr	Price	P/E	P/B	ROE
Avantel Limited	36,86,04,549	138.69	—	1059360.68	0.0%
Ducol Organics And Colours Limited	19,55,275	120.00	—	20089.13	0.0%
Jio Platforms Limited	12,57,181	1,406.40	—	3.57	—
SBI Funds Management Limited	1,01,750	499.55	—	—	—
Tamilnadu Telecommunication Limited	91,314	9.93	—	—	—
Manipal Health Enterprises Limited	76,294	646.70	—	—	—
INDO-MIM Limited	59,042	1,219.50	—	—	—
AvenuesAI Limited	45,138	129.25	153.6	9.51	6.2%
Dhoot Transmission Limited	32,761	1,601.60	—	8.11	—
3M India Limited	31,071	27,570.00	53.8	17.57	32.7%
Alembic Pharmaceuticals Limited	18,970	965.15	22.5	3.19	14.2%

StoxGud checklist: Neutral setup · 6/10

Price above 50-day average
Price above 200-day average
50-day average above 200-day (uptrend)
RSI in healthy 40–70 zone
Positive 1-year return
Return on equity above 15%
Debt to equity below 1
Revenue growing year on year
Net profit margin above 10%
P/E below industry median

A rules-based screen of trend, momentum, quality and valuation. Educational only — not a buy or sell recommendation.

Returns & technicals

1 month+15.8%

6 months+24.3%

1 year+7.1%

3Y CAGR+9.7%

5Y CAGR+4.2%

10Y CAGR+3.9%

50-day avg₹820.39

200-day avg₹779.52

RSI (14)83

FAQs

What is the share price of Alembic Pharmaceuticals Limited?

Alembic Pharmaceuticals Limited (APLLTD) closed at ₹965.15 on NSE on 06 Nov 2026.

What is the market cap of Alembic Pharmaceuticals Limited?

₹18,970 crore at the latest close.

What is the P/E ratio of Alembic Pharmaceuticals Limited?

22.5, on trailing-twelve-month earnings from its filings.

How fast is Alembic Pharmaceuticals Limited growing?

Alembic Pharmaceuticals Limited: revenue has compounded at 9.1% a year over three years; net profit at 25.2% a year. Latest-quarter revenue is up 36.3% year on year, profit up 81.5%.

How profitable is Alembic Pharmaceuticals Limited?

On a trailing-twelve-month basis return on equity is 14.2%, return on capital employed 14.2%, operating margin 16.7%, net margin 9.9%.

How much debt does Alembic Pharmaceuticals Limited have?

Alembic Pharmaceuticals Limited is lightly geared: debt to equity is 0.25 with borrowings of ₹1,490 cr against cash of ₹254 cr (balance sheet of 2026-09-30). Operating profit covers interest 9.4 times.

Financials parsed from Alembic Pharmaceuticals Limited's own XBRL filings to NSE (consolidated), ₹ crore unless marked. Quarterly from MAR '18, annual from FY18, balance sheet from Sep '22. * = derived (full year or half year minus earlier quarters). Information only, not investment advice.